Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition - PubMed (original) (raw)
. 2008 Mar;31(3):599-610.
doi: 10.1183/09031936.00002007. Epub 2007 Nov 21.
Y-J Lai, R Dumitrascu, S S Pullamsetti, R Savai, H A Ghofrani, N Weissmann, C Schudt, D Flockerzi, W Seeger, F Grimminger, R T Schermuly
Affiliations
- PMID: 18032446
- DOI: 10.1183/09031936.00002007
Free article
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
E Dony et al. Eur Respir J. 2008 Mar.
Free article
Abstract
Phosphodiesterase (PDE) inhibitors are currently under investigation for the therapy of pulmonary hypertension. The present study was designed to investigate chronic effects of oral pumafentrine, a mixed selective PDE-3/4 inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension in rats. Treatment with pumafentrine (10 mg.kg(-1) daily) from week 4 to 6 after a single injection of MCT (60 mg.kg(-1)) partially reversed pulmonary hypertension and right heart hypertrophy in rats. In addition, small pulmonary arterial muscularisation, media hypertrophy and decrease in lumen area were largely reversed. Inhibition of smooth muscle proliferation under pumafentrine was demonstrated in vivo as was a pro-apoptotic effect of pumafentrine on vascular cells. Moreover, pumafentrine dose-dependently increased cyclic adenosine monophosphate levels and inhibited proliferation of cultured pulmonary arterial smooth muscle cells. In conclusion, oral pumafentrine partially reverses monocrotaline-induced pulmonary hypertension, lung vascular remodelling and right heart hypertrophy in rats.
Similar articles
- Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F. Schermuly RT, et al. Circ Res. 2004 Apr 30;94(8):1101-8. doi: 10.1161/01.RES.0000126050.41296.8E. Epub 2004 Mar 18. Circ Res. 2004. PMID: 15031263 - Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Schäfer S, et al. Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8. Cardiovasc Res. 2009. PMID: 19131365 - Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F. Schermuly RT, et al. Circulation. 2007 May 1;115(17):2331-9. doi: 10.1161/CIRCULATIONAHA.106.676809. Epub 2007 Apr 16. Circulation. 2007. PMID: 17438150 - The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Reinert JP, Reinert NJ. Reinert JP, et al. J Intensive Care Med. 2021 Jan;36(1):3-8. doi: 10.1177/0885066620957951. Epub 2020 Sep 10. J Intensive Care Med. 2021. PMID: 32909898 Review. - Mutations in Phosphodiesterase 3A (PDE3A) Cause Hypertension Without Cardiac Damage.
Ercu M, Walter S, Klussmann E. Ercu M, et al. Hypertension. 2023 Jun;80(6):1171-1179. doi: 10.1161/HYPERTENSIONAHA.122.19433. Epub 2023 Apr 10. Hypertension. 2023. PMID: 37035914 Review.
Cited by
- Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.
Mohamed NA, Marei I, Crovella S, Abou-Saleh H. Mohamed NA, et al. Int J Mol Sci. 2022 Jan 26;23(3):1404. doi: 10.3390/ijms23031404. Int J Mol Sci. 2022. PMID: 35163328 Free PMC article. Review. - Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Seimetz M, Parajuli N, Pichl A, Bednorz M, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F, Weissmann N. Seimetz M, et al. PLoS One. 2015 Jun 9;10(6):e0129327. doi: 10.1371/journal.pone.0129327. eCollection 2015. PLoS One. 2015. PMID: 26058042 Free PMC article. - Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.
Bubb KJ, Trinder SL, Baliga RS, Patel J, Clapp LH, MacAllister RJ, Hobbs AJ. Bubb KJ, et al. Circulation. 2014 Aug 5;130(6):496-507. doi: 10.1161/CIRCULATIONAHA.114.009751. Epub 2014 Jun 4. Circulation. 2014. PMID: 24899690 Free PMC article. - Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study.
Kolosionek E, King J, Rollinson D, Schermuly RT, Grimminger F, Graham BB, Morrell N, Butrous G. Kolosionek E, et al. Pulm Circ. 2013 Apr;3(2):356-62. doi: 10.4103/2045-8932.114764. Pulm Circ. 2013. PMID: 24015336 Free PMC article. - The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A. Rieder F, et al. PLoS One. 2013;8(2):e56867. doi: 10.1371/journal.pone.0056867. Epub 2013 Feb 28. PLoS One. 2013. PMID: 23468885 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical